Vitamin  ||| S:0 E:8 ||| NNP
D  ||| S:8 E:10 ||| NNP
receptor  ||| S:10 E:19 ||| NN
activation  ||| S:19 E:30 ||| NNS
and  ||| S:30 E:34 ||| CC
cardiovascular  ||| S:34 E:49 ||| JJ
disease  ||| S:49 E:57 ||| NN
Vitamin  ||| S:57 E:65 ||| NNP
D  ||| S:65 E:67 ||| NNP
has  ||| S:67 E:71 ||| VBZ
been  ||| S:71 E:76 ||| VBN
recently  ||| S:76 E:85 ||| RB
associated  ||| S:85 E:96 ||| VBN
with  ||| S:96 E:101 ||| IN
several  ||| S:101 E:109 ||| JJ
renal ||| S:109 E:114 ||| NN
,  ||| S:114 E:116 ||| ,
cardiovascular  ||| S:116 E:131 ||| JJ
and  ||| S:131 E:135 ||| CC
inflammatory  ||| S:135 E:148 ||| JJ
diseases ||| S:148 E:156 ||| NNS
,  ||| S:156 E:158 ||| ,
beyond  ||| S:158 E:165 ||| IN
mineral  ||| S:165 E:173 ||| NN
metabolism  ||| S:173 E:184 ||| NN
and  ||| S:184 E:188 ||| CC
bone  ||| S:188 E:193 ||| NN
health ||| S:193 E:199 ||| NN
.  ||| S:199 E:201 ||| .
This  ||| S:201 E:206 ||| DT
is  ||| S:206 E:209 ||| VBZ
due  ||| S:209 E:213 ||| JJ
in  ||| S:213 E:216 ||| IN
part  ||| S:216 E:221 ||| NN
to  ||| S:221 E:224 ||| TO
widespread  ||| S:224 E:235 ||| JJ
expression  ||| S:235 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
vitamin  ||| S:249 E:257 ||| JJ
D  ||| S:257 E:259 ||| NNP
receptor  ||| S:259 E:268 ||| NN
( ||| S:268 E:269 ||| -LRB-
VDR ||| S:269 E:272 ||| NNP
)  ||| S:272 E:274 ||| -RRB-
on  ||| S:274 E:277 ||| IN
tissues  ||| S:277 E:285 ||| NNS
and  ||| S:285 E:289 ||| CC
cells  ||| S:289 E:295 ||| NNS
such  ||| S:295 E:300 ||| JJ
as  ||| S:300 E:303 ||| IN
heart ||| S:303 E:308 ||| NN
,  ||| S:308 E:310 ||| ,
kidney ||| S:310 E:316 ||| NN
,  ||| S:316 E:318 ||| ,
immune  ||| S:318 E:325 ||| JJ
cells ||| S:325 E:330 ||| NNS
,  ||| S:330 E:332 ||| ,
brain  ||| S:332 E:338 ||| NN
and  ||| S:338 E:342 ||| CC
muscle ||| S:342 E:348 ||| NN
.  ||| S:348 E:350 ||| .
In  ||| S:350 E:353 ||| IN
chronic  ||| S:353 E:361 ||| JJ
kidney  ||| S:361 E:368 ||| NN
disease  ||| S:368 E:376 ||| NN
( ||| S:376 E:377 ||| -LRB-
CKD ||| S:377 E:380 ||| NNP
)  ||| S:380 E:382 ||| -RRB-
and  ||| S:382 E:386 ||| CC
other  ||| S:386 E:392 ||| JJ
chronic  ||| S:392 E:400 ||| JJ
disorders ||| S:400 E:409 ||| NNS
,  ||| S:409 E:411 ||| ,
vitamin  ||| S:411 E:419 ||| VBG
D  ||| S:419 E:421 ||| NNP
deficiency  ||| S:421 E:432 ||| NN
[ ||| S:432 E:433 ||| -LRB-
serum  ||| S:433 E:439 ||| CD
25 ||| S:439 E:441 ||| CD
( ||| S:441 E:442 ||| -LRB-
OH ||| S:442 E:444 ||| NNP
) ||| S:444 E:445 ||| -RRB-
D  ||| S:445 E:447 ||| NNP
< ||| S:447 E:448 ||| SYM
20  ||| S:448 E:451 ||| CD
ng ||| S:451 E:453 ||| CD
/ ||| S:453 E:454 ||| CD
mL ||| S:454 E:456 ||| NN
]  ||| S:456 E:458 ||| -RRB-
is  ||| S:458 E:461 ||| VBZ
very  ||| S:461 E:466 ||| RB
common  ||| S:466 E:473 ||| JJ
and  ||| S:473 E:477 ||| CC
is  ||| S:477 E:480 ||| VBZ
associated  ||| S:480 E:491 ||| VBN
with  ||| S:491 E:496 ||| IN
adverse  ||| S:496 E:504 ||| JJ
outcomes ||| S:504 E:512 ||| NNS
.  ||| S:512 E:514 ||| .
Paricalcitol ||| S:514 E:526 ||| NNP
,  ||| S:526 E:528 ||| ,
a  ||| S:528 E:530 ||| DT
selective  ||| S:530 E:540 ||| JJ
activator  ||| S:540 E:550 ||| NN
of  ||| S:550 E:553 ||| IN
VDR ||| S:553 E:556 ||| NNP
,  ||| S:556 E:558 ||| ,
has  ||| S:558 E:562 ||| VBZ
demonstrated  ||| S:562 E:575 ||| VBN
in  ||| S:575 E:578 ||| IN
several  ||| S:578 E:586 ||| JJ
experimental  ||| S:586 E:599 ||| JJ
and  ||| S:599 E:603 ||| CC
clinical  ||| S:603 E:612 ||| JJ
studies  ||| S:612 E:620 ||| NNS
of  ||| S:620 E:623 ||| IN
diabetic  ||| S:623 E:632 ||| NN
and  ||| S:632 E:636 ||| CC
non-diabetic  ||| S:636 E:649 ||| NNP
CKD  ||| S:649 E:653 ||| NNP
a  ||| S:653 E:655 ||| DT
favourable  ||| S:655 E:666 ||| JJ
profile  ||| S:666 E:674 ||| NN
compared  ||| S:674 E:683 ||| VBN
to  ||| S:683 E:686 ||| TO
other  ||| S:686 E:692 ||| JJ
VDR  ||| S:692 E:696 ||| NNP
activators ||| S:696 E:706 ||| NN
,  ||| S:706 E:708 ||| ,
alone  ||| S:708 E:714 ||| RB
or  ||| S:714 E:717 ||| CC
as  ||| S:717 E:720 ||| IN
add-on  ||| S:720 E:727 ||| JJ
to  ||| S:727 E:730 ||| TO
standard  ||| S:730 E:739 ||| JJ
therapy ||| S:739 E:746 ||| NN
.  ||| S:746 E:748 ||| .
These  ||| S:748 E:754 ||| DT
beneficial  ||| S:754 E:765 ||| JJ
effects  ||| S:765 E:773 ||| NNS
are  ||| S:773 E:777 ||| VBP
mediated  ||| S:777 E:786 ||| VBN
by  ||| S:786 E:789 ||| IN
different  ||| S:789 E:799 ||| JJ
actions  ||| S:799 E:807 ||| NNS
such  ||| S:807 E:812 ||| JJ
as  ||| S:812 E:815 ||| IN
reduction  ||| S:815 E:825 ||| NN
of  ||| S:825 E:828 ||| IN
oxidative  ||| S:828 E:838 ||| JJ
stress ||| S:838 E:844 ||| NN
,  ||| S:844 E:846 ||| ,
inflammation ||| S:846 E:858 ||| NN
,  ||| S:858 E:860 ||| ,
downregulation  ||| S:860 E:875 ||| VBG
of  ||| S:875 E:878 ||| IN
cardiac  ||| S:878 E:886 ||| JJ
and  ||| S:886 E:890 ||| CC
renal  ||| S:890 E:896 ||| JJ
renin  ||| S:896 E:902 ||| JJ
expression ||| S:902 E:912 ||| NN
,  ||| S:912 E:914 ||| ,
downregulation  ||| S:914 E:929 ||| VBG
of  ||| S:929 E:932 ||| IN
calcifying  ||| S:932 E:943 ||| JJ
genes  ||| S:943 E:949 ||| NNS
and  ||| S:949 E:953 ||| CC
direct  ||| S:953 E:960 ||| JJ
vascular  ||| S:960 E:969 ||| JJ
protective  ||| S:969 E:980 ||| JJ
effects ||| S:980 E:987 ||| NNS
.  ||| S:987 E:989 ||| .
Furthermore ||| S:989 E:1000 ||| RB
,  ||| S:1000 E:1002 ||| ,
paricalcitol  ||| S:1002 E:1015 ||| JJ
beneficial  ||| S:1015 E:1026 ||| JJ
effects  ||| S:1026 E:1034 ||| NNS
may  ||| S:1034 E:1038 ||| MD
be  ||| S:1038 E:1041 ||| VB
independent  ||| S:1041 E:1053 ||| JJ
of  ||| S:1053 E:1056 ||| IN
baseline  ||| S:1056 E:1065 ||| FW
serum  ||| S:1065 E:1071 ||| FW
parathyroid  ||| S:1071 E:1083 ||| FW
hormone  ||| S:1083 E:1091 ||| FW
( ||| S:1091 E:1092 ||| -LRB-
PTH ||| S:1092 E:1095 ||| NNP
) ||| S:1095 E:1096 ||| -RRB-
,  ||| S:1096 E:1098 ||| ,
calcium  ||| S:1098 E:1106 ||| NN
and  ||| S:1106 E:1110 ||| CC
phosphate  ||| S:1110 E:1120 ||| JJ
levels ||| S:1120 E:1126 ||| NNS
.  ||| S:1126 E:1128 ||| .
These  ||| S:1128 E:1134 ||| DT
benefits  ||| S:1134 E:1143 ||| NNS
should  ||| S:1143 E:1150 ||| MD
be  ||| S:1150 E:1153 ||| VB
confirmed  ||| S:1153 E:1163 ||| VBN
in  ||| S:1163 E:1166 ||| IN
large  ||| S:1166 E:1172 ||| JJ
and  ||| S:1172 E:1176 ||| CC
well-designed  ||| S:1176 E:1190 ||| JJ
ongoing  ||| S:1190 E:1198 ||| JJ
clinical  ||| S:1198 E:1207 ||| JJ
trials ||| S:1207 E:1213 ||| NNS
.  ||| S:1213 E:1215 ||| .
